BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3:18-34. [PMID: 24696835 DOI: 10.3978/j.issn.2304-3881.2014.02.05] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
Number Citing Articles
1 Wagner A, Wiedmann M, Tannapfel A, Mayr C, Kiesslich T, Wolkersdörfer GW, Berr F, Hauss J, Witzigmann H. Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy--Long-Term Outcome of a Phase II Pilot Study. Int J Mol Sci 2015;16:26619-28. [PMID: 26561801 DOI: 10.3390/ijms161125978] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
2 Zhang WH, Ding PP, Liu L, Wang YL, Lai WH, Han JJ, Han J, Li HW. CO2 or air cholangiography reduces the risk of post-ERCP cholangitis in patients with Bismuth type IV hilar biliary obstruction. BMC Gastroenterol 2020;20:189. [PMID: 32539842 DOI: 10.1186/s12876-020-01341-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Warner WA, Ramcharan W, Harnanan D, Umakanthan S, Maharaj R. A case of distal extrahepatic cholangiocarcinoma with two positive resection margins. Oncol Lett 2016;12:4075-9. [PMID: 27895774 DOI: 10.3892/ol.2016.5174] [Reference Citation Analysis]
4 Coletta M, Montalti R, Pistelli M, Vincenzi P, Mocchegiani F, Vivarelli M. Metastatic breast cancer mimicking a hilar cholangiocarcinoma: case report and review of the literature. World J Surg Oncol. 2014;12:384. [PMID: 25515643 DOI: 10.1186/1477-7819-12-384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
5 Prachayakul V, Kanchanapermpoon J, Thuwajit C, Boonyaarunnate T, Pongpaibul A, Chobson P, Thuwajit P. DNA Methylation Markers Improve the Sensitivity of Endoscopic Retrograde Cholangiopancreatography-Based Brushing Cytology in Extrahepatic Cholangiocarcinoma. Technol Cancer Res Treat 2017;16:1252-8. [PMID: 29484968 DOI: 10.1177/1533034617748090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
6 Hau HM, Meyer F, Jahn N, Rademacher S, Sucher R, Seehofer D. Prognostic Relevance of the Eighth Edition of TNM Classification for Resected Perihilar Cholangiocarcinoma. J Clin Med 2020;9:E3152. [PMID: 33003424 DOI: 10.3390/jcm9103152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jiao X, Yu W, Qian J, Chen Y, Wei P, Fang W, Yu G. ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1. BMC Cancer 2018;18:570. [PMID: 29776401 DOI: 10.1186/s12885-018-4294-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Xu D, Yi W, Chen Y, Ma L, Wang J, Yu G. Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma. Med Oncol 2014;31:261. [PMID: 25344871 DOI: 10.1007/s12032-014-0261-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
9 Kawasaki H, Akazawa Y, Razumilava N. Progress toward improving outcomes in patients with cholangiocarcinoma. Curr Treat Options Gastroenterol 2021;19:153-68. [PMID: 33883870 DOI: 10.1007/s11938-021-00333-2] [Reference Citation Analysis]
10 Peng D, Lu J, Hu H, Li B, Ye X, Cheng N. Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma. J Gastrointest Surg. 2020;24:330-340. [PMID: 30671792 DOI: 10.1007/s11605-018-04086-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Kammerer S, Meister T, Wolters H, Lessing M, Hüsing A, Domagk D, Floer M, Wilms C, Schmidt H, Senninger N, Köhler G, Heinzow HS. Preoperative prediction of curative surgery of perihilar cholangiocarcinoma by combination of endoscopic ultrasound and computed tomography. United European Gastroenterol J 2018;6:263-71. [PMID: 29511556 DOI: 10.1177/2050640617713651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Kovalenko YA, Vishnevsky VA, Chzhao AV, Zharikov YO. [New criteria of radical surgery and long-term outcomes of hilar cholangiocarcinoma management]. Khirurgiia (Mosk) 2018;:4-11. [PMID: 30113586 DOI: 10.17116/hirurgia201884] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Zhao J, Zhang W, Zhang J, Chen YT, Ma WJ, Liu SY, Li FY, Song B. Independent Risk Factors of Early Recurrence After Curative Resection for Perihilar Cholangiocarcinoma: Adjuvant Chemotherapy May Be Beneficial in Early Recurrence Subgroup. Cancer Manag Res 2020;12:13111-23. [PMID: 33376403 DOI: 10.2147/CMAR.S289094] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg 2014;399:693-705. [PMID: 24841192 DOI: 10.1007/s00423-014-1210-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
15 Swensson J, Tirkes T, Tann M, Cui E, Sandrasegaran K. Differentiating IgG4-related sclerosing cholangiopathy from cholangiocarcinoma using CT and MRI: experience from a tertiary referring center. Abdom Radiol (NY). 2019;44:2111-2115. [PMID: 30783729 DOI: 10.1007/s00261-019-01944-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang JK, Hu HJ, Shrestha A, Ma WJ, Yang Q, Liu F, Cheng NS, Li FY. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget 2017;8:45335-44. [PMID: 28484084 DOI: 10.18632/oncotarget.17336] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
17 Buettner S, van Vugt JLA, Gaspersz MP, Coelen RJS, Roos E, Labeur TA, Margonis GA, Ethun CG, Maithel SK, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, IJzermans JNM, van Gulik TM, Pawlik TM, Groot Koerkamp B. Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases. HPB (Oxford) 2017;19:735-40. [PMID: 28549744 DOI: 10.1016/j.hpb.2017.04.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
18 Melenhorst MC, Scheffer HJ, Vroomen LG, Kazemier G, van den Tol MP, Meijerink MR. Percutaneous Irreversible Electroporation of Unresectable Hilar Cholangiocarcinoma (Klatskin Tumor): A Case Report. Cardiovasc Intervent Radiol. 2016;39:117-121. [PMID: 25994516 DOI: 10.1007/s00270-015-1126-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
19 Hu HJ, Mao H, Tan YQ, Shrestha A, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus. 2016;5:551. [PMID: 27190750 DOI: 10.1186/s40064-016-2181-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
20 Yehouenou Tessi TR, Onka B, Drissi MAI, Jerguigue H, Latib R, Omor Y. Klatskin tumor presenting as unresectable perihilar hepatic mass: A case report. Radiol Case Rep 2021;16:2537-41. [PMID: 34276849 DOI: 10.1016/j.radcr.2021.06.027] [Reference Citation Analysis]
21 Inchingolo R, Acquafredda F, Ferraro V, Laera L, Surico G, Surgo A, Fiorentino A, Marini S, de'Angelis N, Memeo R, Spiliopoulos S. Non-surgical treatment of hilar cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(11): 1696-1708 [PMID: 34853644 DOI: 10.4251/wjgo.v13.i11.1696] [Reference Citation Analysis]
22 Chen Y, Cha Z, Fang W, Qian B, Yu W, Li W, Yu G, Gao Y. The prognostic potential and oncogenic effects of PRR11 expression in hilar cholangiocarcinoma. Oncotarget 2015;6:20419-33. [PMID: 25971332 DOI: 10.18632/oncotarget.3983] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
23 Wang A, He Z, Cong P, Qu Y, Hu T, Cai Y, Sun B, Chen H, Fu W, Peng Y. Controlling Nutritional Status (CONUT) Score as a New Indicator of Prognosis in Patients With Hilar Cholangiocarcinoma Is Superior to NLR and PNI: A Single-Center Retrospective Study. Front Oncol 2020;10:593452. [PMID: 33505910 DOI: 10.3389/fonc.2020.593452] [Reference Citation Analysis]
24 Khan J, Ullah A, Matolo N, Waheed A, Nama N, Khan T, Tareen B, Khan Z, Singh SG, Cason FD. Klatskin Tumor in the Light of ICD-O-3: A Population-Based Clinical Outcome Study Involving 1,144 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (2001-2012). Cureus 2021;13:e18941. [PMID: 34815893 DOI: 10.7759/cureus.18941] [Reference Citation Analysis]
25 Hameed A, Pang T, Chiou J, Pleass H, Lam V, Hollands M, Johnston E, Richardson A, Yuen L. Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma - a systematic review and meta-analysis. HPB (Oxford) 2016;18:400-10. [PMID: 27154803 DOI: 10.1016/j.hpb.2016.03.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
26 Schmidt A, Bloechinger M, Weber A, Siveke J, von Delius S, Prinz C, Schmitt W, Schmid RM, Neu B. Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma. United European Gastroenterol J 2016;4:570-9. [PMID: 27536367 DOI: 10.1177/2050640615621235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
27 Daradkeh S. A case series of hilar cholangiocarcinoma: A single surgeon experience over 20-years. Ann Med Surg (Lond) 2021;62:239-43. [PMID: 33537137 DOI: 10.1016/j.amsu.2021.01.059] [Reference Citation Analysis]
28 Xu B, Xu M, Tian Y, Yu Q, Zhao Y, Chen X, Mi P, Cao H, Zhang B, Song G, Zhan YY, Hu T. Matrine induces RIP3-dependent necroptosis in cholangiocarcinoma cells. Cell Death Discov 2017;3:16096. [PMID: 28179994 DOI: 10.1038/cddiscovery.2016.96] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
29 Molina V, Sampson J, Ferrer J, Díaz A, Ayuso JR, Sánchez-Cabús S, Fuster J, García-Valdecasas JC. Surgical treatment of perihilar cholangiocarcinoma: early results of en bloc portal vein resection. Langenbecks Arch Surg 2017;402:95-104. [PMID: 28012034 DOI: 10.1007/s00423-016-1542-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
30 Kwak TW, Park SB, Kim HJ, Jeong YI, Kang DH. Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells. Onco Targets Ther 2017;10:137-44. [PMID: 28053547 DOI: 10.2147/OTT.S112364] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
31 Zhang H, Zhu J, Ke F, Weng M, Wu X, Li M, Quan Z, Liu Y, Zhang Y, Gong W. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015:497942. [PMID: 26448940 DOI: 10.1155/2015/497942] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
32 Lee Y, Choi D, Han S, Han IW, Heo JS, Choi SH. Comparison analysis of left-side versus right-side resection in bismuth type III hilar cholangiocarcinoma. Ann Hepatobiliary Pancreat Surg 2018;22:350-8. [PMID: 30588526 DOI: 10.14701/ahbps.2018.22.4.350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
33 Ba Y, Yue P, Leung JW, Wang H, Lin Y, Bai B, Zhu X, Zhang L, Zhu K, Wang W, Meng W, Zhou W, Liu Y, Li X. Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma. Endosc Int Open 2020;8:E203-10. [PMID: 32010755 DOI: 10.1055/a-0990-9114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Yang SZ, Wang AQ, Du J, Wang JT, Yu WW, Liu Q, Wu YF, Chen SG. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma. World J Gastroenterol 2016; 22(25): 5814-5821 [PMID: 27433094 DOI: 10.3748/wjg.v22.i25.5814] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
35 Jin H, Pang Q, Liu H, Li Z, Wang Y, Lu Y, Zhou L, Pan H, Huang W. Prognostic value of inflammation-based markers in patients with recurrent malignant obstructive jaundice treated by reimplantation of biliary metal stents: A retrospective observational study. Medicine (Baltimore) 2017;96:e5895. [PMID: 28099348 DOI: 10.1097/MD.0000000000005895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
36 Umeda J, Itoi T. Current status of preoperative biliary drainage. J Gastroenterol 2015;50:940-54. [DOI: 10.1007/s00535-015-1096-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
37 Yu Y, Chen Y, Ma J, Yu X, Yu G, Li Z. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma. Tumour Biol 2016;37:4159-67. [PMID: 26490986 DOI: 10.1007/s13277-015-4206-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
38 Li M, Wang J, Song J, Shen F, Song L, Ni X, Suo T, Liu H, Zhong M, Liu H. Preoperative ICG Test to Predict Posthepatectomy Liver Failure and Postoperative Outcomes in Hilar Cholangiocarcinoma. Biomed Res Int 2021;2021:8298737. [PMID: 33681380 DOI: 10.1155/2021/8298737] [Reference Citation Analysis]
39 Kovalenko YA, Zharikov YO. [Portal cholangiocarcinoma: epidemiology, staging principles and aspects of tumor biology]. Khirurgiia (Mosk) 2017;:85-91. [PMID: 29186104 DOI: 10.17116/hirurgia20171185-91] [Reference Citation Analysis]
40 Ryu J, Lee K, Joe C, Joo J, Lee N, Yoo HS. Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report.Integr Cancer Ther. 2018;17:558-561. [PMID: 28745084 DOI: 10.1177/1534735417722225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
41 Li O, Yi W, Yang P, Guo C, Peng C. Relationship between serum MMP-9 level and prognosis after radical resection for Hilar cholangiocarcinoma patients. Acta Cir Bras 2019;34:e201900409. [PMID: 31038586 DOI: 10.1590/s0102-865020190040000009] [Reference Citation Analysis]
42 Chen Y, Hong Z, Lu S, Zhang N, Rong G, Chang X, Liu Z, Bai W, Dong Z, Gao X, Zeng Z, Lu Y. Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis. Med Sci Monit 2018;24:7875-82. [PMID: 30390420 DOI: 10.12659/MSM.907340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Liu H, Cen X, Suo T, Cai X, Yuan X, Shen S, Liu H, Li Y. Trends and Hospital Variations in Surgical Outcomes for Cholangiocarcinoma in New York State. World J Surg 2017;41:525-37. [PMID: 27785554 DOI: 10.1007/s00268-016-3733-5] [Reference Citation Analysis]
44 Tan Y, Qiu BA, Xia NX, Yang YX, Zhu JY, Liu P, An Y, Wu YT. Liver transplantation for hilar cholangiocarcinoma: Analysis of 7 cases. Shijie Huaren Xiaohua Zazhi 2015; 23(2): 313-317 [DOI: 10.11569/wcjd.v23.i2.313] [Reference Citation Analysis]
45 Waghray A, Sobotka A, Marrero CR, Estfan B, Aucejo F, Narayanan Menon KV. Serum albumin predicts survival in patients with hilar cholangiocarcinoma. Gastroenterol Rep (Oxf). 2016; Epub ahead of print. [PMID: 27389416 DOI: 10.1093/gastro/gow021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
46 Rahnemai-Azar AA, Abbasi A, Tsilimigras DI, Weber SM, Pawlik TM. Current Advances in Minimally Invasive Surgical Management of Perihilar Cholangiocarcinoma. J Gastrointest Surg 2020;24:2143-9. [PMID: 32410178 DOI: 10.1007/s11605-020-04639-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Yu G, Yu W, Jin G, Xu D, Chen Y, Xia T, Yu A, Fang W, Zhang X, Li Z, Xie K. PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Mol Cancer 2015;14:193. [PMID: 26576639 DOI: 10.1186/s12943-015-0462-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
48 Staub J, Siddiqui A, Murphy M, Lam R, Parikh M, Pleskow D, Papachristou G, Sharaiha R, Iqbal U, Loren D, Kowalski T, Noor A, Mumtaz T, Yasuda I, Thomas S, Hsaeeb A, Herrick J, Greene T, Adler DG. Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study.Ann Gastroenterol. 2020;33:202-209. [PMID: 32127742 DOI: 10.20524/aog.2020.0451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
49 Xu YC, Cui J, Zhang LJ, Zhang DX, Xing BC, Huang XW, Wu JX, Liang CJ, Li GM. Anti-apoptosis Effect of Decoy Receptor 3 in Cholangiocarcinoma Cell Line TFK-1. Chin Med J (Engl) 2018;131:82-7. [PMID: 29271385 DOI: 10.4103/0366-6999.221271] [Reference Citation Analysis]